Brand & Product Security

Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.

The program intends to address supply chain challenges surrounding product safety, traceability, and counterfeiting.

The Drug Supply Chain Security Act was a major coverage area for Pharma Commerce in 2024.

In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, Jeffrey Bernstein, director of cybersecurity and data privacy for Kaufman Rossin’s risk advisory services, explains the top mistakes healthcare organizations make when building and maintaining their software.

The now-11-year odyssey to track drugs by item through the supply chain will be under a regulatory exemption for up to two years.

With the implementation of unit-level traceability, the collaboration is expected to provide additional visibility not only within the aseptic manufacturing process, but the entire supply chain overall.

A panel offers its perspective on bolstering the temperature monitoring and data sharing process.

With the Nov. 27 deadline fast approaching, is the pharma supply chain ready for full data exchange?

The collaboration is centered around meeting track-and-trace requirements.

In the final part of her interview with Pharma Commerce Editor Nicholas Saraceno, Elizabeth A. Gallenagh, General Counsel and Senior Vice President, Supply Chain Integrity, Healthcare Distribution Alliance, discusses the WEE request process itself, while also providing her thoughts on other sessions that have garnered her attention.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Elizabeth A. Gallenagh, General Counsel and Senior Vice President, Supply Chain Integrity, Healthcare Distribution Alliance, highlights the hard-hitting points that she anticipated will be covered during her session at the 2024 HDA Traceability Seminar.

In the final part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, comments on industry’s preparedness for DSCSA compliance and provides an update as to where pharma is in terms of RFID label adoption.

In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, discusses the best practices that compliance teams should consider as the end of the stabilization period approaches this November.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, highlights the hard-hitting points that she anticipated will be covered during her session at the 2024 HDA Traceability Seminar.

How can industry stakeholders ensure the quality and supply chain security of existing product?

Panel offers suggestions on how compliance teams should be considering handling SOPs, stabilization, and much more.

Session uncovers distributors’ experiences with the Waiver, Exception, or Exemption request process, and how these affect the overall supply chain.

The agency provides an update surrounding the Act’s implementation efforts.

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, predicts the likelihood of stabilization period postponement.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, offers a brief overview of the Drug Supply Chain Security Act.

The agreement revolves around providing and maintaining supply chain transparency.

Webinar dives into the trends, technology, and market necessities that can help tackle these obstacles.

These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.

Radio frequency identification (RFID) not only helps hospitals boost their medication safety standards, it also allows clinicians to continue to provide quality patient care.

The offering reportedly helps avoid product quarantine.

OneScan 7.1 is expected to boost compliance, while also improving pharma supply chain efficiencies.